The fed­er­al gov­ern­ment has on­ly sent four ship­ments of Mer­ck’s Covid-19 an­tivi­ral mol­nupi­ravir (about 400,000 cours­es in each ship­ment) na­tion­wide, and al­ready HHS is re­port­ing … ...

Alex Gorsky, the CEO whose nine-year tenure at J&J was marred by law­suits over the com­pa­ny’s talc ba­by pow­der and opi­oids, will ...

In the midst of their $500 mil­lion pro­gram to build a Covid-19 vac­cine with BioN­Tech, Pfiz­er has an­nounced a siz­able deal to com­mer­cial­ize a … ...

→ An­oth­er cut of pos­i­tive in­ter­im da­ta have lift­ed ex­pec­ta­tions that Ad­verum’s gene ther­a­py that could give the an­ti-VEGF de­vel­op­ers … ...

Just hours af­ter J&J’s on­col­o­gy team bragged about scor­ing a break­through ther­a­py des­ig­na­tion for their BC­MA CAR-T drug, they pulled the wraps off of the mul­ti­ple myelo­ma da­ta for ...

The Fed­er­al Trade Com­mis­sion wants more in­for­ma­tion on Pfiz­er’s takeover of Seagen be­fore it will make a rul­ing on whether it will clear the … ...

DBV Tech­nolo­gies has all but so­lid­i­fied its run­ner up sta­tus in the race to bring a peanut al­ler­gy treat­ment on to the Unit­ed States mar­ket … ...

With the pan­dem­ic po­ten­tial­ly en­ter­ing its lat­er stages, ma­jor drug­mak­ers like Mer­ck have jumped in to aid in the gar­gan­tu­an task of man­u­fac­tur­ing oth­er … ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

A rare dis­ease biotech from the sub­urbs of San Fran­cis­co has re­turned to the ven­ture well for a Se­ries B ex­ten­sion, aim­ing to get its … ...

Just a few days af­ter pric­ing a $150 mil­lion pub­lic of­fer­ing, Io­vance has now closed with 15% more raised, thanks to … ...

Sci­ence 37, one of the star­tups that fu­eled the rise in de­cen­tral­ized clin­i­cal tri­als, will go pri­vate and see its one-time $1 bil­lion val­u­a­tion evap­o­rate … ...